chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 75.0
Sex: F
Vaccine: FLU3
Symptoms: Chills, Nausea, Pain, Pyrexia, Vomiting
Clinical narrative: Initial report received from a health care Professional on 10 October 2012. This case involves 1 of a cluster of 4 patients from the same reporter, with the same vaccine FLUZONE HIGH-DOSE and same lot number UH457A. Information regarding the other 3 patients have been captured in case numbers 2011-09908, 2012-00387, and 2012-00389. A 75-year-old female patient with no concurrent illnesses, had received on 28 September 2011 at 08:30 AM an intramuscular left deltoid injection of FLUZONE HIGH-DOSE (lot number UH457A) at 08:30 AM and 90 minutes later, experienced general body pain, chills, fever, nausea, and vomiting. No relevant tests were performed. Relevant past medical history included: chronic obstructive pulmonary disease, hypertension, coronary artery disease with coronary artery bypass graft times 3, mitral valve repair, allergic rhinitis (seasonal), osteopenia. The patient recovered on an unspecified date. Documents held by sender: Patient history note. Follow up information received on 07 June 2012: FLUZONE HD vaccine Lot number was UH457AA.
Age: 71.0
Sex: F
Vaccine: FLU3
Symptoms: Chills, Nausea, Pain, Pyrexia, Vomiting
Clinical narrative: Initial report received from a health care professional on 10 January 2012. This case involves 1 of a cluster of 4 patients from the same reporter, with the same vaccine FLUZONE HIGH-DOSE and same lot number UH457A. Information regarding the other 3 patients have been capture in case numbers 2011-09908, 2012-00387, and 2012-00388. A 72-year-old female patient with no concurrent illnesses, had received on 20 September 2011 at 09:30 AM an intramuscular left deltoid injection of FLUZONE HIGH-DOSE (lot number UH457A) and 4.5 hours later, experienced general body pain, chills, fever, nausea, and vomiting. No relevant tests were performed. Relevant past medical history included: Bronchiectasis and Irritable Bowel syndrome. The patient recovered on an unspecified date. Documents held by sender: Patient medical history. Follow-up information received on 07 June 2012: The lot number for FLUZONE HIGH-DOSE was updated from UH457A (reported in the initial report) to UH457AA.
Age: 68.0
Sex: M
Vaccine: FLU3, PPV
Symptoms: Chills, Nausea, Pain, Pyrexia, Vomiting
Clinical narrative: Initial report received from a health care professional on 10 January 2012. This case involves 1 of a cluster of 4 patients from the same reporter, with the same vaccine FLUZONE HIGH-DOSE and same lot number UH457A. Information regarding the other 3 patients have been captured in case numbers 2011-09908, 2012-00388, and 2012-00389. A 68-year-old male patient with no concurrent illnesses, had received on 26 September 2011 at 16:00 PM an intramuscular left deltoid injection of FLUZONE HIGH-DOSE (lot number UH457A), and PNEUMOVAX (other manufacturer, lot number not reported) and 30 minutes later, experienced general body pain, chills, fever, nausea, and vomiting. No relevant diagnostic/laboratory data were performed. Relevant medical history included: bronchiectasis-persistent cough treated with Prednisone taper (February 2010), obstructive sleep apnea, ulcerative colitis (resolved 2005), and incidental finding of coronary artery disease on cat scan (CT) in February 2010. The patient recovered on an unspecified date. Documents held by sender: Patient history report. Follow-up information received on 07 June 2012; The patient had received PVAX (Manufacturer: Merck, Lot number: 11582) in the right deltoid area. The patient received FLUZONE HIGH DOSE in left deltoid.
Age: 68.0
Sex: M
Vaccine: FLU3
Symptoms: Chills, Influenza like illness, Malaise, Pyrexia
Clinical narrative: Flu-like symptoms, fever, rigors, malaise.
Age: 20.0
Sex: F
Vaccine: ANTH, SMALL
Symptoms: Injection site papule, Injection site pruritus, Injection site swelling
Clinical narrative: This case was retrieved from the VAERS database via a third party vendor on 26 December 2011 under the reference number 436546. A 20-year-old female patient with no concurrent illnesses, no medical history, and no use of other medications had received the following vaccination on 15 July 2010: ACAM2000 (lot number not reported), and anthrax vaccine (trade name, manufacturer name and lot number unknown). Following the smallpox inoculation the patient had a normal take with resolution of the lesion, but twice a week for the last year she has experienced swelling, papules and pruritus at the site. Symptoms are confined to the scar, and only last a day or so and then are gone. No drainage or systemic symptoms were noted. No laboratory data were performed. The patient was advised to see dermatology. Recovery status was unknown. Documents held by sender: None.
Age: 23.0
Sex: F
Vaccine: FLU3
Symptoms: Erythema, Immediate post-injection reaction, Injection site mass, Migraine, Pain
Clinical narrative: This is a cluster of three patients who had received FLUZONE ID lot number UT4163AA and experienced local reactions. The events for the other patients were captured in case 2011-09486 and 2011-09487. Initial report was received on 03 October 2011 from a healthcare provider. A 23-year-old female patient had received an injection of FLUZONE Intradermal lot number UT4163AA in left deltoid. On the same day immediately after the injection, the patient developed systemic itching especially in her legs, neck and shoulder followed by migraine lasting until early next morning and a quarter size lump and pain. No further information was available at the time of the report. The patient outcome was reported as recovered/resolved. Follow-up information was received on 27 December 2011 from a health care professional. The patient recovered on 12 October 2011. No further information was received at the time of the report. Documents held by sender: none. Follow-up information received on 15 June 2012: The quarter sized lump was at the injection site. The area was painful and reddened. All the events resolved approximately after 1 week of onset.
Age: 23.0
Sex: F
Vaccine: FLU3
Symptoms: Pruritus generalised
Clinical narrative: This is a cluster of three patients who had received FLUZONE ID lot number UT4163AA and experienced local reactions. The events for the other patients were captured in case 2011-09486 and 2011-09487. Initial report was received on 03 October 2011 from a healthcare provider. A 23-year-old female patient had received an injection of FLUZONE Intradermal lot number UT4163AA in left deltoid. On the same day immediately after the injection, the patient developed systemic itching especially in her legs, neck and shoulder followed by migraine lasting until early next morning and a quarter size lump and pain. No further information was available at the time of the report. The patient outcome was reported as recovered/resolved. Follow-up information was received on 27 December 2011 from a health care professional. The patient recovered on 12 October 2011. No further information was received at the time of the report. Documents held by sender: none. Follow-up information received on 15 June 2012: The quarter sized lump was at the injection site. The area was painful and reddened. All the events resolved approximately after 1 week of onset.
Age: 36.0
Sex: F
Vaccine: FLU3
Symptoms: Headache, Injection site erythema, Injection site induration, Injection site pain, Local reaction
Clinical narrative: This is a cluster of three patients who had received FLUZONE ID lot number UT4163AA and experienced local reactions. The events for the other patients were captured in case 2011-09486 and 2011-09488. Initial report was received on 03 October 2011 from a health provider. A 36-year-old female patient had received an injection of FLUZONE Intradermal lot number UT4163AA in the left arm. On the same day, the patient developed induration, redness, pain at site, itching through out entire body starting one hour after shot and lasting about ten hours, headache one hour after and lasting twenty four hours and swollen lymph node in armpit on the same side of injection. No further information was available at the time of the report. The patient outcome was reported as not recovered/not resolved. Follow-up information was received on 27 December 2011 from a health care professional. The patient recovered on approximately 12 October 2011. No further information was received at the time of the report. Documents held by sender: none.
Age: 36.0
Sex: F
Vaccine: FLU3
Symptoms: Lymphadenopathy, Pruritus generalised
Clinical narrative: This is a cluster of three patients who had received FLUZONE ID lot number UT4163AA and experienced local reactions. The events for the other patients were captured in case 2011-09486 and 2011-09488. Initial report was received on 03 October 2011 from a health provider. A 36-year-old female patient had received an injection of FLUZONE Intradermal lot number UT4163AA in the left arm. On the same day, the patient developed induration, redness, pain at site, itching through out entire body starting one hour after shot and lasting about ten hours, headache one hour after and lasting twenty four hours and swollen lymph node in armpit on the same side of injection. No further information was available at the time of the report. The patient outcome was reported as not recovered/not resolved. Follow-up information was received on 27 December 2011 from a health care professional. The patient recovered on approximately 12 October 2011. No further information was received at the time of the report. Documents held by sender: none.
Age: 58.0
Sex: F
Vaccine: FLU3
Symptoms: Axillary pain, Erythema, Feeling abnormal, Induration, Local reaction
Clinical narrative: This is a cluster of three patients who had received FLUZONE ID lot number UT4163AA and experienced local reactions. The events for the other patients were captured in case 2011-09487 and 2011-09488. Initial report was received on 03 October 2011 from a healthcare provider. A 58-year-old female patient had received an injection of FLUZONE Intradermal lot number UT4163AA in left arm. On the same day, the patient developed induration, redness, malaise, total body itching, pain in armpit, enlarged axillary lymph nodes and fever. No further information was available at the time of the report. The patient outcome was reported as not recovered/not resolved. Follow-up information was received from a healthcare professional on 27 December 2011. Verbatim: I will never have this again! I was miserable. The patient outcome was reported as recovered/resolved on 03 November 2011. Follow-up information was received from a healthcare professional on 02 March 2012. All information has been provided in the original VAERS form. There is no additional information to add. Documents held by sender: none.
Age: 58.0
Sex: F
Vaccine: FLU3
Symptoms: Lymphadenopathy, Malaise, Pruritus generalised, Pyrexia
Clinical narrative: This is a cluster of three patients who had received FLUZONE ID lot number UT4163AA and experienced local reactions. The events for the other patients were captured in case 2011-09487 and 2011-09488. Initial report was received on 03 October 2011 from a healthcare provider. A 58-year-old female patient had received an injection of FLUZONE Intradermal lot number UT4163AA in left arm. On the same day, the patient developed induration, redness, malaise, total body itching, pain in armpit, enlarged axillary lymph nodes and fever. No further information was available at the time of the report. The patient outcome was reported as not recovered/not resolved. Follow-up information was received from a healthcare professional on 27 December 2011. Verbatim: I will never have this again! I was miserable. The patient outcome was reported as recovered/resolved on 03 November 2011. Follow-up information was received from a healthcare professional on 02 March 2012. All information has been provided in the original VAERS form. There is no additional information to add. Documents held by sender: none.
Age: 65.0
Sex: F
Vaccine: FLU3
Symptoms: Cold sweat, Diarrhoea, Local swelling, Nausea, Pruritus
Clinical narrative: Initial report was received from a health care professional on 03 November 2011. A female patient (age and date of birth not reported) had received a FLUZONE HIGH-DOSE injection (lot number, site and route of administration not reported). On an unspecified date, the patient experienced nausea, shaking, diarrhea, cold sweats, itching and local swelling. The patients received medical treatment due to the side effects. No further information was available at the time of the report. The patient outcome was not reported. Follow-up information was received from a healthcare professional on 23 January 2012. The patient concomitant medication was reported as thyroid pills. The outcome was reported as recovered/resolved. Follow-up information was received from a healthcare professional on 21 February 2012 reported that the adverse event onset was on 25 September 2011 at 9:30. The outcome remained recovered. Documents held by sender: none.
Age: 65.0
Sex: F
Vaccine: FLU3
Symptoms: Tremor
Clinical narrative: Initial report was received from a health care professional on 03 November 2011. A female patient (age and date of birth not reported) had received a FLUZONE HIGH-DOSE injection (lot number, site and route of administration not reported). On an unspecified date, the patient experienced nausea, shaking, diarrhea, cold sweats, itching and local swelling. The patients received medical treatment due to the side effects. No further information was available at the time of the report. The patient outcome was not reported. Follow-up information was received from a healthcare professional on 23 January 2012. The patient concomitant medication was reported as thyroid pills. The outcome was reported as recovered/resolved. Follow-up information was received from a healthcare professional on 21 February 2012 reported that the adverse event onset was on 25 September 2011 at 9:30. The outcome remained recovered. Documents held by sender: none.
Age: 80.0
Sex: F
Vaccine: FLU3
Symptoms: Chills, Diarrhoea, Feeling hot, Nausea
Clinical narrative: Initial report was received from a company representative who had received the original report from a health care professional on 03 October 2011. Follow-up information (a temporary VAERS report) was subsequently received from a health department on 04 October 2011; and on 13 October 2011 additional follow-up information was received via telephone call to the reporter who is a health care professional. An 80-year-old female patient with no concurrent illnesses and no reported pre-existing medical conditions, had received a first intramuscular right arm injection of FLUZONE HIGH-DOSE (lot number UH459AA) on 03 October 2011 at 12:30 pm and around 5:30 pm that night, the patient began to have chills that were not associated with any fever and by 7:00 pm that night, she experienced nausea and diarrhea and was feeling hot but still denied having any fever. The patient never vomited but did take COMPAZINE suppository due to severe nausea. Medical evaluation was not sought. No relevant diagnostic tests and or laboratory data were completed. As of 04 October 2011 the patient felt "fine" and was reported as being recovered. The reporter for this case is the same as for case numbers 2011-09952 and 2011-09953. Documents held by sender: None.
Age: 41.0
Sex: F
Vaccine: FLU3
Symptoms: Lymphadenopathy, Musculoskeletal stiffness, Myalgia
Clinical narrative: Initial report was received from a company representative on 05 October 2011. A 41-year-old female patient had received FLUZONE Intradermal, lot number UT4163AA (site of administration not reported). On an unspecified date, the patient demonstrated swollen auxiliary lymph nodes and stiff trapezius with soreness. No further information was available at the time of the report. The patient outcome was not reported. Follow-up information was received from a healthcare professional on 03 January 2012. On 03 October 2011, the patient received FLUZONE Intradermal in left arm and onset date was on 04 October 2011. Illness at the time of vaccination, medical history and concomitant medications were reported as none. The patient outcome was reported as recovered/resolved, exact date unknown. Documents held by sender: none.
Age: 49.0
Sex: F
Vaccine: FLU3
Symptoms: Headache, Injection site erythema, Injection site induration, Injection site pain, Musculoskeletal stiffness
Clinical narrative: This is a cluster of 42 patients and their family member who had received FLUZONE ID (lot number not reported) and experienced local reactions. Initial report was received on 17 October 2011 from a healthcare provider. Forty two patients and their family members (gender, age and date of birth not reported) had received FLUZONE INTRADERMAL, (lot number, site and route of administration not reported. On an unspecified date, one of the forty two patients developed a severe radiating headache, beginning in the back of the head and radiating forward along with bilateral neck pain and stiffness. The patient also experienced shaking of the extremity; these symptoms lasted for approximately twenty four hours and gradually subsided. The patients also experienced induration "six inches long" along with redness, firmness and pain at the injection site. Many other patients had less severe site reactions lasting one to five days. No further information was available at the time of the report. The patient's outcome was not reported. Follow-up information was received from a healthcare professional on 27 January 2012. This follow-up report is one out of the forty two patients, no additional information provided for the remaining forty one patients. The patient outcome was reported as recovered/resolved. Follow-up information received on 24 May 2012: The patient was not administered any other vaccines within 4 weeks. The patient was administered FLUZONE vaccine; lot number UT4163AA in right deltoid on 03 October 2011. The patient experienced the events on 03 October 2011 at 14:30, same day after vaccination.
Age: 49.0
Sex: F
Vaccine: FLU3
Symptoms: Neck pain, Tremor
Clinical narrative: This is a cluster of 42 patients and their family member who had received FLUZONE ID (lot number not reported) and experienced local reactions. Initial report was received on 17 October 2011 from a healthcare provider. Forty two patients and their family members (gender, age and date of birth not reported) had received FLUZONE INTRADERMAL, (lot number, site and route of administration not reported. On an unspecified date, one of the forty two patients developed a severe radiating headache, beginning in the back of the head and radiating forward along with bilateral neck pain and stiffness. The patient also experienced shaking of the extremity; these symptoms lasted for approximately twenty four hours and gradually subsided. The patients also experienced induration "six inches long" along with redness, firmness and pain at the injection site. Many other patients had less severe site reactions lasting one to five days. No further information was available at the time of the report. The patient's outcome was not reported. Follow-up information was received from a healthcare professional on 27 January 2012. This follow-up report is one out of the forty two patients, no additional information provided for the remaining forty one patients. The patient outcome was reported as recovered/resolved. Follow-up information received on 24 May 2012: The patient was not administered any other vaccines within 4 weeks. The patient was administered FLUZONE vaccine; lot number UT4163AA in right deltoid on 03 October 2011. The patient experienced the events on 03 October 2011 at 14:30, same day after vaccination.
Age: 45.0
Sex: F
Vaccine: FLU3
Symptoms: Unevaluable event
Clinical narrative: The reporter for this case is the same as for cases 2011-09293, 2011-09589, 2011-09591 and 2011-09592. Follow-up information received from a health care professional on 09 November 2011 reported that no additional information can be provided. Documents held by sender: None.
Age: 31.0
Sex: F
Vaccine: FLU3
Symptoms: Arthralgia, Asthenia, Dizziness, Headache, Musculoskeletal pain
Clinical narrative: Initial report was received on 04 October 2011 from a health care professional which involved a cluster of four patients. This case captures one patient; the other three patients are captured in case numbers 2011-09591, -09592, and -09293. A 31-year-old female patient had received a first dose intramuscular injection of FLUZONE, lot number UH463AB on 20 September 2011 and an unspecified amount of time later on the day of vaccination, she felt dizzy. She went home and later that day she felt weak, pale and felt pain in her legs (heels), wrist and neck. The following morning, she had a fever of 102, a headache and pain in her shoulder and knees. The patient was seen by her primary care physician for follow-up. The patient had no concurrent illness at the time of vaccination. To the reporter's knowledge, the patient had not received any other vaccinations within four week of receiving FLUZONE. Outcome was recovered. Follow-up information was received from a health care professional on 09 November 2011. The patient's date of full recovery was reported as unknown. The reporter has no additional information to add and was unable to obtain additional information. The outcome remained recovered. The reporter for this case is also the same as for case number 2011-09590. Documents held by sender: None.
Age: 31.0
Sex: F
Vaccine: FLU3
Symptoms: Neck pain, Pain in extremity, Pallor, Pyrexia
Clinical narrative: Initial report was received on 04 October 2011 from a health care professional which involved a cluster of four patients. This case captures one patient; the other three patients are captured in case numbers 2011-09591, -09592, and -09293. A 31-year-old female patient had received a first dose intramuscular injection of FLUZONE, lot number UH463AB on 20 September 2011 and an unspecified amount of time later on the day of vaccination, she felt dizzy. She went home and later that day she felt weak, pale and felt pain in her legs (heels), wrist and neck. The following morning, she had a fever of 102, a headache and pain in her shoulder and knees. The patient was seen by her primary care physician for follow-up. The patient had no concurrent illness at the time of vaccination. To the reporter's knowledge, the patient had not received any other vaccinations within four week of receiving FLUZONE. Outcome was recovered. Follow-up information was received from a health care professional on 09 November 2011. The patient's date of full recovery was reported as unknown. The reporter has no additional information to add and was unable to obtain additional information. The outcome remained recovered. The reporter for this case is also the same as for case number 2011-09590. Documents held by sender: None.
Age: 2.0
Sex: M
Vaccine: FLU3
Symptoms: Pyrexia
Clinical narrative: Initial report received on 07 October 2011 from the patient's parent. This case is not medically confirmed at this time. A 2-year-old male patient with no concurrent illnesses had received an intramuscular left deltoid injection of FLUZONE (lot number UH463AB) on 03 October 2011 and at an unspecified amount of time later the same day the patient experienced a fever of 103.9 to 104.6 degrees Fahrenheit and after 72 hours the fever was still continuing and the patient was taken to the emergency department for evaluation. No further information was provided. It was reported the patient had 2 flu vaccinations last year with no reported adverse events. At the time of this report, the patient had not recovered. Documents held by sender: None.
Age: 27.0
Sex: F
Vaccine: FLU3
Symptoms: Computerised tomogram normal, Hypoaesthesia, Paraesthesia
Clinical narrative: Initial report was received on 04 October 2011 from a health care professional which involved a cluster of four patients. This case captures one patient; the other three patients are captured in case numbers 2011-09589, -09592, and -09293. A 27-year-old female patient had received a first dose intramuscular right arm injection of FLUZONE, lot number UH463AB and ten minutes later (also reported as one and a half hours later), she complained of tingling and numbness on one side of the face and arm. She also complained of numbness on the right side. A CT scan of the head without contrast was performed to rule out stroke; results were negative. The patient was diagnosed with "parastesia" and asked to follow-up with neurology as an outpatient. The patient had no concurrent illness, no pre-existing medical conditions and no known allergies. Outcome was unknown. Follow-up information was received from a health care professional on 09 November 2011. The patient had no other medical history except the seasonal allergies. It was confirmed that the patient developed the tingling, numbness on one side of the face, right arm and numbness on right side 10 minutes later. The reporter was unable to obtain any results of any neurological evaluation. No other testing was performed except the CT scan done in the Emergency Department. It was unknown to the reporter if the patient had recovered since she was referred to neurology for follow-up. No additional information available. Follow-up information was received from the patient on 17 January 2012. The patient confirmed that the onset of the tingling was approximately 10 minutes after the vaccination. The patient had no follow-up with a neurologist since she recovered completely. The patient had no sequelae following her recovery. She reported that her CT scan was within normal limits (WNL). The outcome was reported as recovered. The reporter for this case is the same as for case number 2011-09590. Documents held by sender: None.
Age: 51.0
Sex: M
Vaccine: FLU3, PPV
Symptoms: Eye irritation, Swollen tongue
Clinical narrative: Initial report was received from health care professional on 09 October 2011. A 51-year-old male patient had received a FLUZONE injection (route and site of administration not reported) lot number UH462AC on 03 October 2011. On the same day, four hours post vaccination, the patient experienced burning eyes and tongue felt big. The patient was "fine" on the following day. No treatment was provided and denied allergy to eggs. No further information was available at the time of the report. The patient outcome was recovered/resolved. Follow-up information was received from a healthcare professional on 17 January 2012. The patient had received an Intramuscular injection of FLUZONE and PNEUMOVAX in left deltoid. Documents held by sender: none.
Age: 93.0
Sex: F
Vaccine: FLU3
Symptoms: Injection site haematoma, Injection site swelling, Musculoskeletal pain
Clinical narrative: Initial report was received from a healthcare professional on 08 November 2011. A female patient (age and date of birth not reported) had received an injection of INFLUENZA VACCINE (lot number, route and date of administration not reported) in her left arm. On an unspecified date, the patient developed pain in her shoulder, swelling and bruising that spread from below the injection to the elbow. The patient did seek medical treatment due to the side effects. No further information was available at the time of the report. The patient outcome was not reported. Follow-up information was received from a health care professional on 24 February 2012 who also submitted a Temporary VAERS E-Report number E-56498. The patient received an intramuscular injection in the left arm of FLUZONE, lot number UT425AA on 02 October 2011 at 1:00 PM. On 04 October 2011, at 1:00 PM, the patient experienced severe bruising from below injection site to elbow. The patient returned one week later for antibiotic prescription and arm sling. It was unknown if the patient had pre-existing medical conditions and took propranolol concomitantly. The patient's outcome was unknown. Documents held by sender: None.
Age: 56.0
Sex: M
Vaccine: SMALL
Symptoms: Arthralgia, Chills, Listless, Myalgia
Clinical narrative: This case was retrieved from the VAERS database via a third party vendor on 26 December 2011 under reference number 437632. A 56-year-old male patient with no concurrent illnesses, no reported medical history had received the following vaccination on 05 October 2011: ACAM2000 (lot number UH469AB, this is not a valid sanofi pasteur lot number for this product). The same day the patient complained of joint pain, achy muscles, chills and listlessness. No laboratory data were performed. The patient was taking concomitant medications of daily baby aspirin, 3000mg of fish oil a day, 1500mg of niacin a day, and 1500mg of Saw Palmetto a day. The patient recovered on an unspecified date. Documents held by sender: None.
Age: 41.0
Sex: M
Vaccine: SMALL
Symptoms: Erythema
Clinical narrative: This case was retrieved from the VAERS database via a third party vendor on 26 December 2011 under reference number 437856. A 41-year-old male patient with no concurrent illnesses and no reported medical history had received the following vaccination on 01 October 2011: ACAM2000 (lot number VV04-003-A). On 07 October 2011 (also reported as around 3:00 am on 11 October 2011 in the free text narrative field), which was 6 days post inoculation, the patient stated his arm was red and it had traveled "down here" (patient was pointing to his armpit). Upon assessment, the outer area of the arm was cleaned with a BETADINE swab and the skin was wiped with gauze. The scabbed site was re-dressed with a 2x2 gauze that was secured and covered with paper tape. The patient recovered on an unspecified date. There may be a discrepancy between the event date field and the onset date information in the free text narrative field in the data reported. Latency has been calculated using the event date. Documents held by sender: None.
Age: 30.0
Sex: M
Vaccine: SMALL
Symptoms: Acne, Chills, Pyrexia, Rash macular, Vaccination complication
Clinical narrative: This case was received on 26 December 2011 via a third party query tool search on the VAERS database, under reference number 438105. A 30-year-old male patient received the following vaccination on 03 October 2011: a left arm ACAM2000, SP Biologics Co. lot number VV04003A. The patient had  no current illnesses and no medical history. On 12 October 2011, the patient's primary vaccination site enlarged with multiple satellite lesions. He developed fever and chills. A diffuse macular rash presented to the trunk and face.  He was sent to the Emergency Room with the diagnosis "or" acne. No laboratory information was reported. The outcome was reported as recovered. Documents held by sender: None.
Age: 30.0
Sex: M
Vaccine: SMALL
Symptoms: Vaccination site swelling
Clinical narrative: This case was received on 26 December 2011 via a third party query tool search on the VAERS database, under reference number 438105. A 30-year-old male patient received the following vaccination on 03 October 2011: a left arm ACAM2000, SP Biologics Co. lot number VV04003A. The patient had  no current illnesses and no medical history. On 12 October 2011, the patient's primary vaccination site enlarged with multiple satellite lesions. He developed fever and chills. A diffuse macular rash presented to the trunk and face.  He was sent to the Emergency Room with the diagnosis "or" acne. No laboratory information was reported. The outcome was reported as recovered. Documents held by sender: None.
Age: 26.0
Sex: M
Vaccine: ANTH, FLUN3, SMALL, TYP
Symptoms: Erythema, Eschar, Headache, Injection site pain, Injection site pruritus
Clinical narrative: This case was received on 26 December  2011 via a third party query tool search on the VAERS database, under reference number 438562. A 26-year-old male patient received the following vaccinations on 05 October 2011: a left arm ACAM2000, lot number VV04003A, a subcutaneous right arm injection of TYPHIM VI, sanofi pasteur SA lot number E0549, intranasal of FLUMIST (MEDIMMUNE, lot number 501107P), and right arm intramuscular injection of BIOTHRAX (EMERGENT, lot number FAV289). The patient had no current illnesses. His medical history was not reported. On 13 October 2011, the patient developed enlarged lymph nodes, headache, tenderness and itching at the site as well as worry over appearance of the site. The erythema measured 3 cm x 3 cm and the eschar measured 1.5 cm x 0.75 cm. The area surrounding the deltoid was tender without drainage building or streaking. The outcome was reported as unknown. Documents held by sender: None.
Age: 26.0
Sex: M
Vaccine: ANTH, FLUN3, SMALL, TYP
Symptoms: Injection site reaction, Lymphadenopathy
Clinical narrative: This case was received on 26 December  2011 via a third party query tool search on the VAERS database, under reference number 438562. A 26-year-old male patient received the following vaccinations on 05 October 2011: a left arm ACAM2000, lot number VV04003A, a subcutaneous right arm injection of TYPHIM VI, sanofi pasteur SA lot number E0549, intranasal of FLUMIST (MEDIMMUNE, lot number 501107P), and right arm intramuscular injection of BIOTHRAX (EMERGENT, lot number FAV289). The patient had no current illnesses. His medical history was not reported. On 13 October 2011, the patient developed enlarged lymph nodes, headache, tenderness and itching at the site as well as worry over appearance of the site. The erythema measured 3 cm x 3 cm and the eschar measured 1.5 cm x 0.75 cm. The area surrounding the deltoid was tender without drainage building or streaking. The outcome was reported as unknown. Documents held by sender: None.
Age: 20.0
Sex: F
Vaccine: SMALL
Symptoms: Dizziness, Dyspnoea, Lethargy, Malaise, Nausea
Clinical narrative: This case was received on 26 December 2011 via a third party query tool search on the VAERS database, under reference number 439031. A 20-year-old female patient received the following vaccination on 12 October 2011: a ACAM2000, SP Biologics Co. lot number VV04003A). The patient had no current illnesses and took no other medications. The patient had a recent history of Methicillin-resistant Staphylococcus aureus (MRSA) which was resolved with antibiotics and was cleared by primary care manager to receive vaccine prior to administration. On 13 October 2011, the patient developed shortness of breath with increasing lethargy and malaise. The shortness of breath waxed and waned over the past week with nocturnal episodes the worse. The patient denied chest pain or radiation since onset. She also had transient nausea and dizziness over the same period. The patient was sent via Emergency Medical Service (EMS) to Emergency Room (ER) to rule out myo/endo/pericarditis. The outcome was not reported. Documents held by sender: None.
Age: 84.0
Sex: F
Vaccine: FLU3
Symptoms: Balance disorder, Diarrhoea, Influenza like illness, Pyrexia, Vomiting
Clinical narrative: Initial report was received 14 October 2011 from a health care professional; and follow-up was received from a nurse on 19 October 2011. This non-serious case involves 1 of a cluster of 2 elderly female patients from the same reporter. Information regarding the other patient (who was hospitalized) is captured in serious case number 2011-10151. An elderly female patient had received a dose of FLUZONE HIGH-DOSE, lot number UH457AA on an unspecified date, and an unspecified amount of time later, the patient had vomiting. No additional information was provided at the time of the report. Outcome was not reported. Follow-up information was received on 02 March 2012 from a health care professional. The patient's outcome was reported as recovered (date not reported). Follow-up information received from a healthcare professional on 19 April 2012, reported an 84 year-old-female patient received dose one of a left deltoid intramuscular injection of FLUZONE HIGH-DOSE, sanofi pasteur Inc., lot number UH457AA on 05 October 2011 at 11:00AM. Two hours later, "by 1:00PM" (also reported as 06 October 2011 at 1:00AM), the patient started vomiting, had fever, flu-like symptoms, trouble with balance and loose stools, which required a doctor visit. Past medical history and concomitant medications were not reported. Illness at time of vaccination was reported as none. The patient reported no diagnostic or laboratory tests were done. The patient's outcome was reported as recovered on an unspecified date (per reporter, date not reported by patient).
Age: 83.0
Sex: M
Vaccine: FLU3
Symptoms: Injection site reaction, Rash pruritic
Clinical narrative: Initial report received on 12 October 2011 from a pharmacist. An 83-year-old patient (gender not reported) with no concurrent illnesses and medical history of Neomycin allergy had received an intramuscular left deltoid injection of FLUZONE (lot number UH453AB) on 03 October 2011 and 2 days later experienced an itchy rash at the injection site the size of a fist. The patient had no received any other vaccinations within 4 weeks of receiving the FLUZONE vaccination. No further information was provided. Recovery status was unknown. Follow-up information was received from a healthcare professional on 03 January 2012. When the patient is exposed to neomycin he develops a localized rash. The patient was not evaluated by a physician for his rash that developed after receiving FLUZONE; and no treatment was given. NO further information was available at the time of the report. The patient outcome was reported as recovered/resolved on 18 October 2011. Documents held by sender: None.
Age: 30.0
Sex: F
Vaccine: ANTH, SMALL
Symptoms: Axillary pain, Blood creatine phosphokinase MB normal, Blood creatine phosphokinase normal, C-reactive protein normal, Chest pain
Clinical narrative: This case was received on 26 December 2011 via a third party query tool search on the VAERS database, under reference number 439429. A 30-year-old female patient received the following vaccinations on 23 September 2011: a ACAM2000, SP Biologics Co. lot number VV04003A and an injection of BIOTHRAX, EMERGENT lot number FAV281. The patient had no medical history and had no current illnesses. She took CELEBREX 200 milligrams (mg) daily. On 30 September 2011, the patient had axillary pain and then became intertwined with achy chest pain over the weekend. On 03 October 2011, the patient was admitted to the hospital for chest pain and axillary pain which started 7-9 days after the vaccines. The patient's laboratory findings on 02 October 2011 were as follows: Troponin T Cardiac serum <0.010 ng/ml; creatine kinase 129 U/L; creatinine kinase MB 1.5 ng/ml. On 03 October 2011, the patient had the following laboratory findings: C-reactive protein 0.4 mg/dl; ESR 7mm/hr; cardiac panel which showed a creatine kinase 117 U/L, creatine kinase MB 1.5 ng/mL; Troponin T cardiac <0.010 ng/mL and another creatine kinase of 103 U/L. The outcome was reported as recovered. Documents held by sender: None.
Age: 30.0
Sex: F
Vaccine: ANTH, SMALL
Symptoms: Red blood cell sedimentation rate normal, Troponin T, Troponin normal
Clinical narrative: This case was received on 26 December 2011 via a third party query tool search on the VAERS database, under reference number 439429. A 30-year-old female patient received the following vaccinations on 23 September 2011: a ACAM2000, SP Biologics Co. lot number VV04003A and an injection of BIOTHRAX, EMERGENT lot number FAV281. The patient had no medical history and had no current illnesses. She took CELEBREX 200 milligrams (mg) daily. On 30 September 2011, the patient had axillary pain and then became intertwined with achy chest pain over the weekend. On 03 October 2011, the patient was admitted to the hospital for chest pain and axillary pain which started 7-9 days after the vaccines. The patient's laboratory findings on 02 October 2011 were as follows: Troponin T Cardiac serum <0.010 ng/ml; creatine kinase 129 U/L; creatinine kinase MB 1.5 ng/ml. On 03 October 2011, the patient had the following laboratory findings: C-reactive protein 0.4 mg/dl; ESR 7mm/hr; cardiac panel which showed a creatine kinase 117 U/L, creatine kinase MB 1.5 ng/mL; Troponin T cardiac <0.010 ng/mL and another creatine kinase of 103 U/L. The outcome was reported as recovered. Documents held by sender: None.
Age: 29.0
Sex: M
Vaccine: FLU3, SMALL
Symptoms: Fatigue, Joint stiffness, Muscular weakness, Petechiae
Clinical narrative: This case was received on 26 December 2011 via third party query tool search on the VAERS database, under reference number 439558. A 29-year-old male patient received the following vaccinations on 20 September 2011: ACAM2000, SP Biologics Co. lot number VV04003A) and an intramuscular injection of AFLURIA, CSL LIMITED lot number 04949221A. The patient had no current illnesses noted and took no other medications. He had an allergy to SEPTRA and sulfa based drugs which caused a reaction-rash. On 21 September 2011, the patient developed bilateral hand weakness, joint stiffness in the hands and elbows, fatigue, an petechiae on right arm/chest. The patient required an Emergency visit. The outcome was reported as unknown. Documents held by sender: None.
Age: 41.0
Sex: F
Vaccine: SMALL
Symptoms: Arthralgia, C-reactive protein, Full blood count, Metabolic function test, Pyrexia
Clinical narrative: This case was received on 26 December 2011 via a third party query tool search on the VAERS database, under reference number 439753. A 41-year-old female patient received the following vaccination on 07 October 2011: a left arm ACAM2000 (lot number VV04003A). The patient had a history of latex and iodine allergy but had no medical issues. The patient had no current illness. Her concomitant medications included ZYRTEC as needed. On 12 October 2011, the patient developed joint pains in hands, elbow,  shoulders, hips, knees, feet and a low grade temperature. She required an Emergency visit. The patient had the following laboratory testing performed but no results reported: C-reactive protein,  full blood count, metabolic function test, red blood cell sedimentation rate and urinalysis. The outcome was reported as recovered. Documents held by sender: None.
Age: 41.0
Sex: F
Vaccine: SMALL
Symptoms: Red blood cell sedimentation rate, Urine analysis
Clinical narrative: This case was received on 26 December 2011 via a third party query tool search on the VAERS database, under reference number 439753. A 41-year-old female patient received the following vaccination on 07 October 2011: a left arm ACAM2000 (lot number VV04003A). The patient had a history of latex and iodine allergy but had no medical issues. The patient had no current illness. Her concomitant medications included ZYRTEC as needed. On 12 October 2011, the patient developed joint pains in hands, elbow,  shoulders, hips, knees, feet and a low grade temperature. She required an Emergency visit. The patient had the following laboratory testing performed but no results reported: C-reactive protein,  full blood count, metabolic function test, red blood cell sedimentation rate and urinalysis. The outcome was reported as recovered. Documents held by sender: None.
Age: 68.0
Sex: F
Vaccine: FLU3
Symptoms: Arthralgia
Clinical narrative: Initial non-serious report received from a consumer on 27 September 2011 under the local reference number 11-0636. A 68-year-old previously healthy female patient with an unknown medical history had received an intramuscular dose of FLUZONE HIGH-DOSE (batch number UH436AA) in the right deltoid on 26 September 2011. On 27 September 2011, 24 hours after vaccination, the patient complained of pain in side of the left knee. The patient denied swelling. At the time of the report, the patient had not recovered. Follow-up information was received from a healthcare professional on 03 January 2012. On 28 September 2011, before the event subsided, the pain occurred in the second leg (knee area) as well. The patient did not get a physical exam by her physician. The patient outcome was reported as resolved/recovered on 28 September 2011. Documents held by sender: None.
Age: 21.0
Sex: M
Vaccine: ANTH, FLUN3, SMALL, TYP
Symptoms: Activities of daily living impaired, Local reaction, Skin lesion, Vaccinia virus infection
Clinical narrative: This case was retrieved from the VAERS database via a third party vendor on 26 December 2011 under reference number 440302. A 21-year-old male patient with no concurrent illnesses, no known drug allergies (reported as NKDA) and pre-existing eczema as a child had received the following vaccinations on 07 October 2011: ACAM2000 (lot number VV04-003-A), TYPHIM VI (lot number E0302), BIOTHRAX (manufacturer Emergent, lot number FAV281), and FLUMIST (manufacturer MedImmune, lot number 501096P). On 17 October 2011, ten days after receiving the vaccination, the patient reportedly was found to have the beginning of vaccinia because the lesions were on the opposite side of where they would be if it were eczema. Due to the proximity of his leaving and the possibility of a vaccinia, the patient was suspended and received a 10-day home leave and was to be re-evaluated in a week. Public health, and the patient's co-workers were alerted of the patient's delayed leaving. It was felt at the time that the wife was out of danger as she had been previously immunized against smallpox. The patient was released with work/duty limitations. Diagnosis was vaccinia from vaccination localized from "25 October 2011 to 15 November 2011" (discrepancy exists in onset date in the event date field and free text reported). The patient was not able to leave for 3 weeks. The patient was to follow-up with primary care manager (reported as PCM) in 1 week or sooner if there were problems. Recovery status was reported as "unknown". Documents held by sender: None.
Age: 33.0
Sex: F
Vaccine: FLU3
Symptoms: Hypersensitivity, Urticaria
Clinical narrative: Initial report was received from a health care professional on 25 October 2011. A female patient had received FLUZONE (lot number, route, site and date of administration not reported) and an unspecified amount of time later experienced and allergic reaction requiring an emergency room evaluation. No further information was available at the time of the report. The patient's outcome was not reported. Follow-up information was received from a health care professional on 05 March 2012. The patient was a 33-year-old who received FLUZONE on 20 October 2011. The patient presented to the emergency room with allergic reaction and hives. The onset was just prior to arrival on 20 October 2011. The course/duration of symptoms was improving, the location was diffuse and the character of symptoms was hive-like. The degree at onset was minimal and the degree at present was minimal. The potential allergen was the flu shot. The patient had no prior episodes. Therapy included prescription medications including BENADRYL. The patient denied swelling, denied difficulty swallowing and denied nausea and vomiting. The review of symptoms was negative. The physical examination was normal except generalized urticaria on the skin. The differential diagnosis was allergic reaction and urticaria. The patient received IV PEPCID and improved. The patient's condition was listed as improved and she was discharged to home with ZANTAC. The patient had no illness at the time of vaccination and an allergy to latex and DEMEROL. The patient had a past medical history of hypertension, allergic rhinitis, obesity, hyperventilating and a c-section. The patient's family history included hypertension. No further information was available at the time of the report. The patient's outcome was recovered. Follow-up information was received on 06 April 2012 from a health care professional. The patient had no diagnostic or laboratory results and no allergy testing was performed. The patient recovered on 20 November 2011. Documents held by sender: Medical records.
Sex: F
Vaccine: FLU3
Symptoms: Nausea, Pruritus
Clinical narrative: Itching; Nausea. Documents held by sender: none.
Age: 29.0
Sex: F
Vaccine: SMALL
Symptoms: Erythema, Flushing, Pruritus
Clinical narrative: This case was received on 23 January 2012 via a third party query tool search on the VAERS database, under reference number 440925. A 29-year-old female patient with no concurrent illnesses received the following vaccinations on 24 September 2011: ACAM2000 (lot number VV04-003-A) and the following day had pruritus with scattered redness patches, non fluid filled on torso and arm. Her face was flush with splotches. Recovery status was unknown. Documents held by sender: none.